Dyno Therapeutics

Our CSO and Cofounder Adrian Veres and Head of Partnership Success Tyson Bertmaring spoke with Dave West of Scrum.org about what makes AAV capsid engineering a fascinating design problem for AI, the value of building cohesive cross-functional teams to tackle complex science, and lessons learned along the way. Listen to their podcast episode here: https://lnkd.in/eakya_dn

Join us tomorrow for our #NYTechWeek fireside chat where NVIDIA's Director of Digital Biology Anthony Costa and Dyno's CEO & Cofounder Eric Kelsic will be discussing the next frontiers of AI in biology– from opportunities to real-world challenges. Come early and stay after: 🍷 Drinks and light bites will be served from 6:30 to 9:00 PM. 🤝 Meet others in the AI + bio community before and after the talk. 🧠 Stick around for a mini Turing Test competition where you’ll try your hand at spotting the difference between machine- and human-generated content. Reserve your spot here: https://lnkd.in/earNf4nh

That’s a wrap on #ASGCT25! We had a great time sharing our latest scientific progress and initiatives—from the launch of three new capsids for CNS, eye, and neuromuscular targeting, to the announcement of the Dyno Frontiers Program and our upcoming GATC conference this fall. Learn more at dynotx.com, and stay tuned for more exciting updates in the year ahead!

Here’s a recap of the data we presented at #ASGCT25 this afternoon on our newest neuromuscular capsid: Dyno-3hv! As shared by Dr Megan Cramer in her talk, Dyno-3hv is the first capsid of its kind optimized for highly efficient delivery to the multiple tissues affected by neuromuscular disorders, including heart, skeletal muscle and CNS. You can learn more about this capsid at dynotx.com/3hv and about partnering with Dyno at dynotx.com/gene-delivery.

Tune into this episode of BiotechTV at #ASGCT25, where Brad Loncar and Eric Kelsic talk more in depth about the science behind the CNS, eye, and neuromuscular capsids we launched this week, as well as the Dyno Frontiers Program and upcoming GATC conference, and how they’re designed to help end users access better therapies by tackling delivery challenges at scale.

Here’s a recap of the data we presented at #ASGCT25 this afternoon on our newest eye capsid: Dyno-4z2! As shared by Dr Amanda Miles in her talk, Dyno-4z2 is a breakthrough capsid for ocular delivery, with highly efficient delivery to the retina through intravitreal injection, and field-leading targeting of bipolar cells in the inner nuclear layer. You can learn more about this capsid at dynotx.com/4z2 and about partnering with Dyno at dynotx.com/gene-delivery.

Join us this Saturday at #ASGCT25 for a presentation on our new vector for neuromuscular gene delivery, Dyno-3hv: the first capsid of its kind optimized for highly efficient delivery to the multiple tissues affected by neuromuscular disorders, including heart, skeletal muscle and CNS. ►Presenter: Megan Cramer, Ph.D. ►Date and time: Saturday, May 17, 2025, 11:45 AM – 12:00 PM CT ►Location: New Orleans Theater A ►Abstract number: #413

Don’t miss tomorrow’s #ASGCT25 presentation on Dyno’s newest ocular capsid, Dyno-4z2: an AI-designed AAV capsid with highly efficient delivery to the retina through intravitreal injection, with field-leading targeting of bipolar cells in the inner nuclear layer. ►Presenter: Amanda Miles, Ph.D. ►Date and time: Friday, May 16, 2025, 2:30 PM – 2:45 PM CT ►Location: New Orleans Theater A ►Abstract number: #280

Here’s a recap of the data we presented at #ASGCT25 this afternoon on our newest brain capsid: Dyno-ahq! As shared by Dr Mugdha Deshpande in her talk, Dyno-ahq is a breakthrough capsid for CNS delivery, with pan-brain tropism and exceptional liver detargeting. You can learn more about this capsid at dynotx.com/ahq and about partnering with Dyno at dynotx.com/gene-delivery.

Today, we announced the Dyno Frontiers Program, an initiative designed to demonstrate the transformative therapeutic potential of innovative genetic payloads. The new Dyno Frontiers Program offers therapeutic developers access to Dyno’s gene delivery technology and scientific expertise, towards demonstrating the transformative therapeutic potential of innovative genetic payloads. Interested therapeutic developers are invited to apply at https://lnkd.in/eg9KZkPa. More info about the program here: https://lnkd.in/eUP-E_ZD